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Introduction:
Homocystinuria is an inborn error of metabolism most
frequently caused by cystathionine β-synthase (CBS)
deficiency. Homocysteine (Hcy), methionine (Met) and other
metabolites of Hcy accumulate in the body of affected
patients, leading to clinical manifestations such as dislocation
of the optic lents, osteoporosis, mental retardation, and
thromboembolism. Despite the fact that thromboembolism
represent the major cause of morbidity and the most
frequent cause of death in CBS-deficient patients, the cause
of cardiovascular changes found in homocystinuria remain
unclear. In this work, we evaluated the lipid profile (total
cholesterol, HDL cholesterol, LDL cholesterol, oxidized LDL
cholesterol, apolipoprotein A-1) and the activities of the
 Controls Group A Group B 
Total cholesterol 
(mg/dl) 
185,62 ± 56,53 118,75 ± 38,48* 125,78 ± 28,36* 
HDL cholesterol 
(mg/dl) 59,35 ± 19,43 38,98 ± 9,62** 33,27 ± 9,99** 
LDL cholesterol 
(mg/dl) 106,65 ± 53,95 71,14 ± 30,45 78,76 ± 29,21 
Oxidized LDL 
cholesterol (U/L) 
 
19,15 ± 7,44 
 
14,77 ± 4,76 
 
13,12 ± 5,75 
Apolipoprotein A 
(mg/dL) 
 
200,98 ± 29,57 
 
156,32 ± 33,81** 
 
141,34 ± 20,79** 
Hcy (µmol/L) 5,84 ± 2,52 266,5 ± 66,71*** 137,8 ± 104,3*  
 
Table 1. Lipid profile and Hcy levels in CBS-deficient patients at diagnosis (Group A), CBS-deficient
patients under treatment (Group B) and controls.
Data represent mean ± standard deviation
*p < 0.01 statistically different from controls (ANOVA, followed by the Duncan multiple range test).
**p < 0.001 statistically different from controls (ANOVA, followed by the Duncan multiple range test).
enzymes paraoxonase (PON1) and butyrylcholinesterase
(BuChE) in plasma of CBS-deficient patients, at diagnosis and
during the treatment.
Materials and Methods:
CBS-deficient patients were recruited from the Medical
Genetic Service of Hospital de Clínicas de Porto Alegre, Brazil.
Patients were divided in two groups: group A consisted of 9
patients with CBS deficiency at diagnosis (median age:10
years; range: 4 – 27 years) and group B consisted of 9 patients
with CBS deficiency under treatment (median age:19 years;
range: 12 – 32 years). All patients were diagnosed after the
neonatal period by identification of abnormal elevated
concentrations of tHcy and Met in plasma. The treatment
consisted of a protein-restricted diet supplemented by
pyridoxine (median dose: 500mg/day; range: 100 –
750mg/day), folic acid (median dose: 5mg/day; range: 2 –
5mg/day), betaine (median dose: 6g/day; range: 2 – 6g/day)
and vitamin B12 (median dose: 1mg IM /month). The average
duration of treatment was 10 years (range: 5 – 20 years).
Plasma samples were obtained from and 12 healthy
Fig. 1. PON1 activity in CBS-deficient patients at diagnosis (Group A,
n=9), CBS-deficient patients under treatment (Group B, n=9) and
controls (n=12). Data represent mean ± standard deviation, **p<0.001
statistically different from controls (ANOVA, followed by the Duncan
multiple range test).
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***p < 0.0001 statistically different from controls (ANOVA, followed by the Duncan multiple range
test).
individuals with comparable age and sex (median age:25
years; range: 4 – 34 years). The present study was approved
by the Ethics Committee of Hospital de Clínicas de Porto
Alegre, Brazil. Informed consent was obtained according to
the guidelines of the committee.
Results:
It was verified a significant decrease in HDL cholesterol and
apolipoprotein A1 levels in the both groups of CBS-deficient
patients (at diagnosis and under treatment) when compared
to controls. PON1 activity was also significantly lower in the
both groups of CBS-deficient patients when compared to
controls, which may be related with an Hcy-dependent
oxidation of any group important to catalytic activity of the
enzyme that favors the atherogenesis. BuChE activity was
significantly increased only in CBS-deficient patients at
diagnosis and it is known that this enzymatic activity is
positively associated with cardiovascular risk factors.
Apoio: CNPq, FAPERGS, CAPES, FIPE/HCPA
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Fig. 2. BuChE activity in CBS-deficient patients at diagnosis (Group A,
n=8), CBS-deficient patients under treatment (Group B, n=8) and
controls (n=11). Data represent mean ± standard deviation, *p<0.01
statistically different from controls and from group B (ANOVA,
followed by the Duncan multiple range test).
Conclusion:
Evaluated together, our results demonstrated that treated or
not CBS-deficient patients presented important alterations in
lipid metabolism. This work contributes to the understanding
of the responsible mechanisms of vascular lesions in CBS-
deficient patients.
